ArticleMolecular genetics and genomics : MGG2026
Activation of the PI3K/AKT pathway by EDIL3 induces EMT and promotes tumor progression in clear cell renal cell carcinoma.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
EDIL3 is a secreted extracellular matrix protein implicated in tumor progression; however, its biological function in clear cell renal cell carcinoma (ccRCC) remains poorly defined. In this study, we systematically investigated the expression profile, functional roles, and underlying mechanisms of EDIL3 in ccRCC. We found that EDIL3 was significantly upregulated in ccRCC tissues and cell lines. Functional assays demonstrated that EDIL3 markedly enhanced the proliferative, migratory, and invasive capacities of ccRCC cells. Mechanistically, EDIL3 promoted epithelial-mesenchymal transition (EMT), as evidenced by downregulation of E-cadherin and upregulation of N-cadherin and Vimentin. Further analyses revealed that EDIL3 activated the PI3K/AKT signaling pathway, and sustained activation of this pathway effectively reversed the suppression of EMT and malignant phenotypes induced by EDIL3 depletion.Collectively, our findings identify EDIL3 as a critical regulator of ccRCC cell malignancy by linking extracellular matrix dynamics to PI3K/AKT-driven EMT programs, thereby providing mechanistic insight into its role in ccRCC progression.
Indexed as
Identifiers
41779200What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.